A phase I study of bevacizumab and sunitinib in metastatic renal cell carcinoma patients
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab; Sunitinib
- Indications Renal cancer
- Focus Adverse reactions
- 11 Nov 2008 Biomarkers information updated
- 05 Jun 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 31 Jan 2008 Status changed from suspended to in progress according to NCT.